Japan Eyes Cutting Reimbursement For COVID-19 Drugs

Large Reduction For Xocova?

 
• By Lisa Takagi

Japan will end full reimbursement coverage for COVID-19 therapeutic drugs from October, after downgrading the status of the virus to the same level as seasonal flu in early May. As authorities discuss the possible coverage reduction, a larger than usual price cut may also be applied to Shionogi's oral COVID antiviral Xocova.

Balancing NHI system and the market’s demand for accessible drugs for COVID-19 can be a challenging task.
Japan's challenge to balance NHI system and market demand for COVID-19 drugs • Source: Shutterstock

More from Japan

More from Asia